

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

MCA-205

RRID:CVCL_VR90

Type: Cell Line

Proper Citation

RRID:CVCL_VR90

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_VR90

Proper Citation: RRID:CVCL_VR90

Description: Cell line MCA-205 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Disease: Mouse fibrosarcoma

Comments: Characteristics: Excellent model for studying the immune responses to tumor cells and for supporting the development of targeted cancer immunotherapies (Millipore=SCC173).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: MCA-205

Synonyms: MCA 205, MCA205

Cross References: Lonza:1177, Millipore:SCC173, Wikidata:Q95985779

ID: CVCL_VR90

Record Creation Time: 20220427T220749+0000

Record Last Update: 20260829T234551+0000

Ratings and Alerts

No rating or validation information has been found for MCA-205.

No alerts have been found for MCA-205.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Fu R, et al. (2026) Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. bioRxiv : the preprint server for biology.

Islam R, et al. (2025) TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis. Molecular oncology, 19(8), 2431.

Alicea Pauneto CDM, et al. (2025) Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. Immunity.

Holay N, et al. (2025) INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering. Journal for immunotherapy of cancer, 13(5).

Allard D, et al. (2025) Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis. Cancer research, 85(4), 692.

Hunt EG, et al. (2024) Acetyl-CoA carboxylase obstructs CD8+ T cell lipid utilization in the tumor microenvironment. Cell metabolism.

Wu J, et al. (2024) A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R β strengthens T cell-mediated anti-tumor therapies. Cell reports. Medicine, 5(10), 101747.

Mannion J, et al. (2024) A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. Immunity, 57(7), 1514.

Knorr DA, et al. (2024) Fc γ RIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research, 12(3), 322.

Charalambous A, et al. (2024) Tumor Microenvironment Reprogramming Improves Nanomedicine-Based Chemo-Immunotherapy in Sarcomas. Molecular cancer therapeutics, 23(11), 1555.

Montégut L, et al. (2024) Acyl-coenzyme A binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance. Molecular cancer, 23(1), 187.

Riesenberg BP, et al. (2022) Stress-Mediated Attenuation of Translation Undermines T-cell Activity in Cancer. *Cancer research*, 82(23), 4386.

Zhao L, et al. (2022) Interference of immunogenic chemotherapy by artificially controlled calreticulin secretion from tumor cells. *Methods in cell biology*, 172, 99.

Zhao L, et al. (2021) A genotype-phenotype screening system using conditionally immortalized immature dendritic cells. *STAR protocols*, 2(3), 100732.